Breaking Finance News

Citigroup Inc. reporeted on Portola Pharmaceuticals Inc (NASDAQ:PTLA), bumping down its stock price target to $24.00 earlier today

Showing a price of $19.22, Portola Pharmaceuticals Inc (NASDAQ:PTLA) traded 2.48% higher on the day. With the last stock close down 4.39% relative to the 200-day moving average, compared to the S&P 500 which has fallen -0.01% over the date range. PTLA has been tracking to a 50-day average of $23.55 and two hundred day average of $24.68. Volume of trade was was up over the average, with 1,609,536 shares of PTLA changing hands over the typical 1,085,080 shares.

In a report announced on 8/19/2016 Citigroup Inc. reduced the target price of Portola Pharmaceuticals Inc (NASDAQ:PTLA) from $40 to $24 reporting a possible upsideof 0.25%.

On Friday August 19 2016, Citigroup reported about Portola Pharmaceuticals Inc(NASDAQ:PTLA) dropped the target price from $40.00 to $24.00. At the time, this suggested an upside of 0.19%.

Recent Performance Graphic:

Portola Pharmaceuticals Inc (NASDAQ:PTLA)

Also covering Portola Pharmaceuticals Inc’s price target, a total of 5 firms have issued a report on the stock. The one year target stock price is $47.80 with two analysts rating the company a strong buy, four firms rating the stock a buy, 0 analysts rating the stock a hold, 0 rating the company to underperform, and finally 0 analysts rating the company as sell.

Portola Pharmaceuticals Inc has a one-year low of $18.20 and a one-year high of $57.96 and has a market capitalization of $0.0.

General Company Details For Portola Pharmaceuticals Inc (NASDAQ:PTLA)

Portola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients who have limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company’s Syk is a mediator of immune response in various types of immune cells. The Company has a program of highly selective Syk inhibitors, one of which is partnered with Ora Inc. Its Betrixaban is an oral once-daily inhibitor of Factor Xa. Its Andexanet alfa, is an orphan drug, and which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor. The Company is developing orally available kinase inhibitors to treat hematologic disorders and inflammation.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.